ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2431

Association Of T Follicular Helper / Th17 T Cell and Memory B Cell Populations In Rheumatoid Arthritis With Disease Activity and Therapy With TNF Antagonists

Marc C. Levesque1, Camilla Macedo2, Lisa Boyette2, Kevin Hadi3, Erich R Wilkerson4, Diana Metes2, Larry W. Moreland5 and Mandy J. McGeachy6, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Univeristy of Pittsburgh, Pittsburgh, PA, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Medicine, Division of Rheumatology and Clinical Immunology, Univeristy of Pittsburgh, Pittsburgh, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, B cells, monocytes and rheumatoid arthritis (RA), T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Autoreactive memory B cells and T cells contribute to the pathogenesis of rheumatoid arthritis (RA) through production of antibodies and cytokines that activate monocytes and joint stromal cells.  Memory B cells and T cells react to similar citrullinated joint proteins, and have been shown to decrease in response to therapy with TNF inhibitors.  However, interactions between these cells have not been interrogated in the same RA patients in relation to disease activity and therapy response.

Methods: We obtained RA PBMC samples from the Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry.  26 subjects were selected based on disease activity (19 patients with active disease (Clinical Disease Activity Index (CDAI) > 2.8) and 7 patients in remission (CDAI ≤ 2.8)).  Subjects were treated with methotrexate (MTX) (n = 14) or with a TNF inhibitor plus MTX (n = 12).  Nine healthy subjects served as controls.  We performed flow cytometry on PBMC to analyze monocyte and T and B cell subsets.  Mann-Whitney tests were used for unpaired comparisons of T and B cell populations from RA subjects and healthy controls.  Spearman’s rho was determined for correlations of T and B cell populations with disease activity.

Results: The frequencies of peripheral blood classical, non-classical and intermediate monocytes were not different between RA subjects and healthy controls, and were not associated with disease activity or therapy.  Of CD4+ T helper (Th) subsets, CXCR5high T follicular helper (TFh)-like cell subsets that co-expressed CCR6 (CXCR5highTh17) were increased in RA compared to healthy controls (p = 0.0082), and there was a trend towards increased frequencies of CXCR5highTh17 cells in patients with active disease compared to remission.  In contrast, CXCR3+TFh cells (CXCR5highTh1) showed the opposite pattern, and were decreased in RA patients with active disease (p < 0.0004), but unchanged between those in remission and healthy controls.  This resulted in significantly higher CXCR5+Th17:CXCR5+Th1 ratios in active RA patients compared to healthy controls (p < 0.01) or to patients in remission (p < 0.05).  For these T cell populations, there was no association with treatment or between T helper subsets and memory B cell subsets.  However, the proportion of isotype-switched memory B cells was positively correlated with disease activity in the MTX group (rho = 0.54, p = 0.05) but not TNF inhibitor plus MTX group (rho = 0.37, p = 0.24).

Conclusion: TFh/Th17 cells and memory B cells were both increased in RA while TFh/Th1 cells were decreased in active RA.  Disease activity correlated with class-switched memory B cells in subjects treated with MTX but not with TNF antagonists. Although TNF inhibitors have been reported to decrease Th17 cell populations, our results suggest that disease activity rather than therapy may have a greater effect on frequencies of TFh/Th17 and TFh/Th1 cells.


Disclosure:

M. C. Levesque,

Genentech and Biogen IDEC Inc.,

2,

Genentech and Biogen IDEC Inc.,

5;

C. Macedo,
None;

L. Boyette,
None;

K. Hadi,
None;

E. R. Wilkerson,

Genentech and Biogen IDEC Inc.,

2;

D. Metes,
None;

L. W. Moreland,

Genentech and Biogen IDEC Inc.,

2;

M. J. McGeachy,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-t-follicular-helper-th17-t-cell-and-memory-b-cell-populations-in-rheumatoid-arthritis-with-disease-activity-and-therapy-with-tnf-antagonists/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology